Objectives: Previous studies that have assessed the risk of developing epilepsy have failed to account for the competing risk of death, significant in the elderly where epilepsy incidence is highest. We report the lifetime risk for epilepsy, accounting for the competing risk of mortality.
incidence of epilepsy increases dramatically beginning at age 60 years and the elderly are the fastest growing segment of the general population in developed countries. We present estimates of the LR for epilepsy in a population-based study from Rochester, MN, during the period 1960 through 1979.
METHODS Previous studies in Rochester, MN, have assessed the incidence of seizure disorders from 1935 to 1984. 1 Our case group is restricted to the subjects who developed epilepsy between 1960 and 1979. Epilepsy was defined as 2 or more unprovoked seizures and unprovoked seizures as a seizure without an identified proximate precipitant. Incident epilepsy was ascertained through the records-linkage system of the Rochester Epidemiologic Project, which links all medical records from medical facilities in Southeastern Minnesota and includes inpatient, outpatient, emergency room, doctor's private office, and home visits. We reviewed the medical records of all residents with a diagnosis of seizure, convulsion, epilepsy, or conditions known to be related to seizures.
Factors measured. The age at epilepsy diagnosis was used in calculating cumulative incidence and LR. Separate analysis considered epilepsy diagnosis at age Ն60 years, using 5-year age groups. Epilepsy etiology was categorized as progressive symptomatic, remote symptomatic, or idiopathic/cryptogenic. 4 Deaths in the general population of Rochester, MN, were obtained by age, gender, and calendar year [5] [6] [7] [8] to calculate LR.
The study was approved by the IRB at Columbia University. Data were collected by chart abstraction and consent was not obtained from subjects.
Statistical analysis.
We defined Rj as the total population at risk at any given age j.
Cumulative incidence.
We let e j equal the total number of cases in the study period at each age j. h j estimates the hazard, which is the probability that a person of age j will develop epilepsy in the next instant of time. 9 We calculated h j by dividing e j /R j . The survival probability (S j ) at each age j was calculated, using the following:
For example, to determine the cumulative hazard until age 5, h j was summated from the age of 0 until 5 with the negative result of the summation exponentiated (note: S j ϭ 1 when j ϭ 0). Next, the hazard (hj) was multiplied by the survival probability at age j Ϫ 1 (f j ϭ h j [S jϪ1 ]), representing the age-specific incidence at age j. Finally, cumulative incidence was calculated as the summation of the age-specific incidences from age 0 to age j (F j ϭ ⌺f j ).
The cumulative incidence of epilepsy does not reflect the competing risk of death prominent in the elderly where epilepsy incidence is most increased. Instead, deaths are considered to be equivalent to withdrawals with the same assumed but unassessed future risk of epilepsy as subjects who are censored alive.
Remaining lifetime risk. Unlike cumulative incidence, the LR adjusts for the competing risk of death by considering deaths and incident epilepsy as events. That is, people who die are con-sidered to have zero risk for developing epilepsy. To calculate LR, the variable h j * represented the adjusted hazard, computed as the deaths plus cases (e j *) divided by R j (h j * ϭ e j */R j ). The adjusted hazard was used to calculate the adjusted survival probability, U j * (U j * ϭ exp[Ϫ1* ⌺(h j *)]). The variable f j * was calculated by multiplying the original hazard (h j ) by U j * Ϫ1 , the age-specific incidence adjusted for the competing risk of death (fj* ϭ h j [U j * Ϫ1 ]). This permitted calculation of LR, a summation of the age-specific incidences from age 0 to age j adjusted for the competing risk of death (F j * ϭ ⌺f j *). The cumulative incidence was 0.9% to age 20, 1.7% to age 50, and 3.4% to age 80 ( figure 1A) . The LR was 0.9% to age 20, 1.6% to age 50, and 3.0% to age 80. The curves begin to noticeably diverge at age 70 years when mortality begins to increase, demonstrating that cumulative incidence overestimates LR when the competing risk of mortality becomes large. Relative to LR, cumulative incidence was 6.6% higher at age 70 -74 and 17.8% higher at age 80 -84. These trends were observed for men and for women ( figure 1, B and C) and by epilepsy etiology, with the greatest difference observed for progressive symptomatic epilepsy where incidence increases most dramatically in the elderly (table e-1 and figures e-1, e-2, and e-3 on the Neurology ® Web site at www. neurology.org).
RESULTS
Remaining lifetime risk by age. Remaining LR sets the risk at 0 for the beginning age or age group, whereas LR considers the risk from age 0 onward. To highlight the impact of increasing mortality on differences between cumulative incidence and remaining LR for epilepsy, we examined these measures in the elderly overall and by gender by 5-year age groups (table 1). With increasing mortality from age 70 -74 years onward, remaining LR becomes lower than cumulative incidence.
We also examined the remaining LR over a 40year period, beginning at different ages (table 2) . For a 20-year-old without epilepsy, the LR for epilepsy is 0.23% over the next 5 years, 0.6% over the next 10 years, and 1.06% over the next 40 years or until age 60 years. In contrast, for a 50year-old without epilepsy, the LR for epilepsy is 0.15% over the next 5 years, 0.71% over the next 20 years, and 2.58% over the next 40 years or until age 90 years. DISCUSSION Based upon the LR calculations in this population-based study, 1 in 26 people will develop epilepsy during their lifetime. Men have a higher risk of developing epilepsy (1 of every 21 males) than women (1 of every 28 females). This approach is more accurate than cumulative incidence, and it is better comprehended by most people who are accustomed to similar statistics provided for cancer.
Cumulative incidence has been used in etiologic studies of epilepsy and for public health purposes to determine health care needs of a population. It is useful in children, because mortality is low, and in etiologic studies. However, cumulative incidence may overestimate the risk for developing diseases with high incidence in the elderly where significant mortality represents a competing risk. This is because the cumulative incidence assumes that individuals who die before they can be observed to have the disease are assumed to have developed the disease at the same rate as those who survive. 11 In contrast, LR adjusts for the competing risk of death by setting the risk for disease after death at 0, and it provides a better measure of the risk for developing epilepsy given survival to a specific age, particularly in the elderly where the risk of death due to other causes is high. 12 LR can be used for individual risk prediction with the usual caveats because it is a measure based upon population estimates 3 and not upon factors related to any one individual (e.g., familial life expectancy, risk factors). Even with this limitation, LR is informative about the number who will develop epilepsy, 1 in 26 people in the population, which may be easier to communicate than the percentage of people who will develop epilepsy by a given age.
The LR for epilepsy from Rochester, MN, is likely similar to that for other developed countries with comparable sociodemographics for the specific birth cohorts. However, our findings may not be applicable to other populations with markedly different death rates due to a low life expectancy, such as developing countries. Additionally, our findings will not be applicable to other populations that may have a greater incidence of epilepsy. These limitations of the LR are small, however, since the distribution of different etiologic groups may also differ in different age groups with very different expectations of life in these settings. The LR for specific epilepsy etiologies may be greater in populations where treatments of stroke, for example, have markedly improved survival thereby increasing the time period in which such individuals are at increased risk for developing epilepsy.
Our data are drawn from 1960 to 1979. This does not compromise the validity of the comparison between cumulative incidence and LR. However, with the increase in life expectancy, the LR of epilepsy should be greater than what we report, particularly for males. Between 1970 and 2005 in the United States, life expectancy has risen from 67.1 years to 75.2 years for males and from 74.7 years to 80.4 years for females. 13 Using the methodology described in this article, LR has been assessed for other neurologic disorders, including stroke, 3 dementia, 3 and Parkinson disease. 14 In the elderly, the LR for epilepsy is 0.31% for a 65-to 69-year-old and 1.6% to age 80 for a 50-year-old. In Framingham, MA, the LR is 14.3% for first stroke to age 85 for a 55-yearold and 4.0% for dementia to age 80 for a 65-year-old.
Our data suggest that almost 12 million individuals in the United States will develop epilepsy in their lifetime. The impact of this calculation is greatest in the elderly who have the highest incidence, an important concern given the aging population. Information obtained from the LR has several important uses. LR provides physicians with an estimate of an individual's risk for developing epilepsy over his or her remaining lifetime, a risk estimate that readily translates into numbers of people who are expected to develop epilepsy, and it provides useful information for health care planners estimating services needed for epilepsy. 
